Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Men with metastatic castration-resistant prostate cancer that has progressed after hormonal therapy and chemotherapy, and whose tumours show PSMA on a PET scan, can now receive lutetium-PSMA, which extends life, controls pain and is usually better tolerated than further chemotherapy. It has established a new treatment class in which a scan decides who gets the matching radioactive drug, and it is now being tested earlier in the disease (PSMAfore, PSMAddition).
Germline and tumour testing for homologous recombination repair genes is now standard in metastatic prostate cancer, and olaparib is approved for BRCA-mutated disease after a hormonal agent.
Radium-223 is an option for symptomatic bone-predominant castration-resistant prostate cancer, now less used since lutetium-PSMA, and should not be combined with abiraterone after the ERA 223 fracture signal.
Abiraterone became a standard treatment for metastatic castration-resistant prostate cancer and, after later trials, for hormone-sensitive and high-risk localised disease.
Query for this cancer: (TITLE:"Metastatic castration-resistant prostate cancer" OR ABSTRACT:"Metastatic castration-resistant prostate cancer" OR TITLE:"mCRPC" OR ABSTRACT:"mCRPC" OR TITLE:"Metastatic CRPC" OR ABSTRACT:"Metastatic CRPC" OR TITLE:"Castration-resistant metastatic prostate cancer" OR ABSTRACT:"Castration-resistant metastatic prostate cancer" OR TITLE:"Hormone-refractory prostate cancer older term" OR ABSTRACT:"Hormone-refractory prostate cancer older term") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Metastatic castration-resistant prostate cancer, not a curated reading list.